One work that analyzed the protective effect of HT in BRAF-mutated PTCs reported that patients had significantly less extracapsular extension (57.6% vs. 29.6%, p = 0.001) and smaller tumor sizes (p = 0.028), but similar rates of LNM (35.9% vs. 31.5%, p = 0.509) [31]. The gene discussed is BRAF; the disease is neoplasm.